PTC Therapeutics, Inc.
Reconciliation of GAAP to Non-GAAP Projected Full Year 2019 R&D and SG&A Expense
Low End of Range
High End of Range
Projected GAAP R&D and SG&A expense
Less: projected non-cash, stock-based compensation expense
Projected non-GAAP R&D and SG&A expense
Subscribe to our Free Newsletters!